NOT
FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY,
IN WHOLE OR IN PART, IN OR INTO OR WITHIN THE UNITED STATES,
AUSTRALIA, NEW ZEALAND, CANADA, SOUTH AFRICA OR JAPAN, OR ANY
MEMBER STATE OF THE EEA, OR ANY OTHER JURISDICTION WHERE, OR TO ANY
OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR
BREACH OF ANY APPLICABLE LAW OR REGULATION. PLEASE SEE THE
IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES
OF THE MARKET ABUSE REGULATION (EU) 596/2014 WHICH FORMS PART OF UK
LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK
MAR").
15 October 2024
IXICO PLC
("IXICO" or
the "Company")
Result of Retail
Offer
Further to the announcement dated 8
October 2024, IXICO plc (AIM: IXI), the medical imaging advanced
analytics company delivering insights in neuroscience, is pleased
to announce that, following the closing of the Retail Offer on the
BookBuild platform on 14 October 2024, 516,244 New Ordinary Shares
will be issued at the Issue Price of 9.5 pence per Retail Offer
Share in connection with the Retail Offer, raising an additional
£49,043.
Consequently, conditional on the
passing of the Resolutions at the General Meeting, 41,315,792
Placing Shares, 789,472 Subscription Shares
and 516,244 Retail Offer Shares, resulting in a total of 42,621,508
new Ordinary Shares, will be issued in relation to the Fundraising,
raising total gross proceeds of £4.05 million.
Admission and Total Voting Rights
Application has been made for the
Retail Offer Shares to be admitted to trading on AIM ("Admission").
Admission is expected to take place at 8.00 a.m. on or around 28
October 2024.
The Retail
Offer Shares will, when issued, be credited
as fully paid and will rank pari passu in all respects with
existing Ordinary Shares including the right to receive all
dividends and other distributions declared, made or paid after
their date of issue.
Following Admission, the total
number of Ordinary Shares in the capital of the Company in issue
will be 92,668,598 with each Ordinary Share carrying the right to
one vote. There are no shares held in treasury and therefore,
following Admission, the total number of voting rights in the
Company will be 92,668,598. The above figure may be used by
Shareholders as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in, the share capital of the Company
under the FCA's Disclosure, Guidance and Transparency
Rules.
For the purposes of UK MAR, the
person responsible for arranging release of this announcement on
behalf of the Company is Bram Goorden, Chief Executive
Officer.
Capitalised terms used in this
announcement have the meaning given to them in the Placing and
Retail Offer announcement dated 8 October 2024, unless otherwise
defined in this announcement.
For
further information please contact:
|
IXICO plc
|
+44 (0) 20 3763 7499
|
|
Bram Goorden, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets Limited
(Nominated adviser and sole broker)
|
+44 (0) 20 7220 0500
|
|
Giles Balleny / Dan
Hodkinson (Corporate
Finance)
|
|
|
Nigel Birks (Life Sciences
Specialist Sales)
|
|
|
Harriet Ward (Corporate
Broking)
|
|
|
Michael F Johnson / Tamar Cranford
Smith (Sales)
|
|
About IXICO
IXICO is dedicated to
delivering insights in neuroscience to help transform the
advancement of investigational therapies for neurological diseases,
such as Huntington's disease, Parkinson's disease and Alzheimer's
disease. The Company's purpose is to advance medicine and human
health by turning data into clinically meaningful information,
providing valuable new insights in neuroscience by supporting
pharmaceutical companies across all phases of CNS clinical
research. IXICO's goal is to be a leading advocate of
artificial intelligence in medical image analysis.
IXICO has developed and
deployed breakthrough data analytics, at scale, through its remote
access technology platform, to improve the return on investment in
drug development and reduce risk and uncertainty in clinical trials
for the Company's pharmaceutical clients.
More information is available
on www.IXICO.com and follow us on X
(formerly Twitter) @IXICOnews
